Treats edema. Sold as Edecrin. Every FDA application for this active ingredient: 1 branded and 10 generic.
As of Nov 15, 2026, FDA lists 11 applications for Ethacrynic Acid (sold as Edecrin), first approved Jan 10, 1967, with 0 new uses approved and 0 published complete response letters.
| Ethacrynic Acid | Part D | $5.1M | -16% | 4,266 |
| Edecrin | Part D | $461K | -21% | 43 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Pharmacokinetics of Drugs Administered to ChildrenPediatric ALL · Duke University | — | Recruiting | Mar 29, 2018 |
| Jan 10, 1967 | EdecrinNDA 16092 · New molecular entity | Bausch | 31 | Marketed |
| Jun 30, 2016 | Ethacrynic AcidANDA 205609 | Adaptis | 0 | Marketed |
| Feb 23, 2017 | Ethacrynic AcidANDA 207262 | Hikma | 0 | Discontinued |
| Jul 21, 2017 | Ethacrynic AcidANDA 208501 | Ph Health | 0 | Discontinued |
| May 8, 2018 | Ethacrynic AcidANDA 208805 | Amneal Pharms Co | 0 | Marketed |
| Jul 24, 2018 | Ethacrynic AcidANDA 205709 | Alvogen | 0 | Discontinued |
| Jul 12, 2019 | Ethacrynic AcidANDA 211809 | Agnitio | 0 | Marketed |
| Aug 27, 2019 | Ethacrynic AcidANDA 211232 | Sciegen Pharms | 0 | Marketed |
| Sep 6, 2019 | Ethacrynic AcidANDA 211719 | Lupin | 0 | Marketed |
| Feb 19, 2020 | Ethacrynic AcidANDA 212417 | Upsher Smith Labs | 0 | Marketed |
| Oct 19, 2020 | Ethacrynic AcidANDA 213240 | Chartwell Rx | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Hikma
Lupin